RecruitingNot ApplicableNCT06974617
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine: A Randomized Clinical Trial
Sponsor
Cairo University
Enrollment
64 participants
Start Date
May 15, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria3
- Age 18 and 65 years.
- Both sexes.
- Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.
Exclusion Criteria4
- Patients with medication over use headache.
- Bleeding disorders.
- Abnormal neurological examination.
- History of allergy to local anesthetics or BOTOX.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSphenopalatine block
Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.
DRUGBotulinum Toxin Type A
Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06974617
Related Trials
Cannabis for the Prophylactic Treatment of Migraine
NCT039721241 location
Blocking Sphenopalatine Ganglion by Intranasal Lidocaine Spray in Partial Turbinectomy Surgeries
NCT072996301 location
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713106 locations
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT0681050561 locations
The RECLAIM Study.
NCT0645044411 locations